Related references
Note: Only part of the references are listed.Preparation and Evaluation of Gefitinib Containing Nanoliposomal Formulation for Lung Cancer Therapy
Seema Rohilla et al.
BIONANOSCIENCE (2022)
Impact of ecDNA: A mechanism that directs tumorigenesis in cancer drug Resistance-A review
Sumel Ashique et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2022)
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
Arlene Chan et al.
CLINICAL BREAST CANCER (2021)
Expressions of ZNF436, β-catenin, EGFR, and CMTM5 in breast cancer and their clinical significances
Zhi Chen et al.
EUROPEAN JOURNAL OF HISTOCHEMISTRY (2021)
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Anti-inflammatory and anticancer activities of Naringenin-loaded liquid crystalline nanoparticles in vitro
Ridhima Wadhwa et al.
JOURNAL OF FOOD BIOCHEMISTRY (2021)
Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy
Adileh Ayati et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Role of HGF/MET in liver cancer
Gaurav Gupta et al.
FUTURE MEDICINAL CHEMISTRY (2021)
EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma
Runping Fang et al.
NATURE COMMUNICATIONS (2021)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Jacqueline V. Aredo et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Circular RNA-encoded oncogenic E-cadherin variant promotes glioblastoma tumorigenicity through activation of EGFR-STAT3 signalling
Xinya Gao et al.
NATURE CELL BIOLOGY (2021)
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial
Gregory J. Riely et al.
CANCER DISCOVERY (2021)
A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling
Ai-lin Yang et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2021)
A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study
Huseyin Abali et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2021)
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned
Lorenzo Belluomini et al.
CELLS (2021)
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study
Zhi Peng et al.
CANCER COMMUNICATIONS (2021)
The Role of Glycosyltransferases in Colorectal Cancer
Cecilia Fernandez-Ponce et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review)
Jingyi He et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2021)
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Keunchil Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Rutin loaded liquid crystalline nanoparticles inhibit non-small cell lung cancer proliferation and migration in vitro
Keshav Raj Paudel et al.
LIFE SCIENCES (2021)
Osimertinib in EGFR-Mutated Lung Cancer
Wenhua Liang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Denis M. Collins et al.
CLINICAL CANCER RESEARCH (2021)
Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy
Afshin Derakhshani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Peter T. Harrison et al.
SEMINARS IN CANCER BIOLOGY (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
beta-Elemene inhibits the metastasis of multidrug-resistant gastric cancer cells through miR-1323/Cbl-b/EGFR pathway
Mingming Deng et al.
PHYTOMEDICINE (2020)
Comprehensive pharmacogenomic characterization of gastric cancer
Jason K. Sa et al.
GENOME MEDICINE (2020)
HER2-positive advanced breast cancer treatment in 2020
Marcelle G. Cesca et al.
CANCER TREATMENT REVIEWS (2020)
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
Vito Amodio et al.
CANCER DISCOVERY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors
Maria Vittoria Dieci et al.
CANCER TREATMENT REVIEWS (2020)
Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
Yu-Tao Liu et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer
Akira Inoue
PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES (2020)
Dietary Crocin is Protective in Pancreatic Cancer while Reducing Radiation-Induced Hepatic Oxidative Damage
Hamid A. Bakshi et al.
NUTRIENTS (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Systemic therapy for metastatic HER2-positive breast cancer
Philip Bredin et al.
SEMINARS IN ONCOLOGY (2020)
Antiproliferative effects of boswellic acids-loaded chitosan nanoparticles on human lung cancer cell line A549
Neeta Solanki et al.
FUTURE MEDICINAL CHEMISTRY (2020)
ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer
Cletus A. Arciero et al.
CLINICAL BREAST CANCER (2019)
Hydrogen bond analysis of the EGFR-ErbB3 heterodimer related to non-small cell lung cancer and drug resistance
Avirup Ghosh et al.
JOURNAL OF THEORETICAL BIOLOGY (2019)
MICAL-L2 potentiates Cdc42-dependent EGFR stability and promotes gastric cancer cell migration
Pengxiang Min et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
The Correlation between EGFR and Androgen Receptor Pathways: A Novel Potential Prognostic Marker in Gastric Cancer
Shahrzad S. Fard et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2019)
PD-L1/PD-1 Axis in Glioblastoma Multiforme
Jakub Litak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Current Approaches in NSCLC Targeting K-RAS and EGFR
Veronica Aran et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
The tumor-suppressive function of miR-1296-5p by targeting EGFR and CDK6 in gastric cancer
Yan Jia et al.
BIOSCIENCE REPORTS (2019)
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2019)
Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer
Jennifer W. Carlisle et al.
FUTURE ONCOLOGY (2019)
A Third Shot at EGFR: New Opportunities in Cancer Therapy
Salvador Guardiola et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer
Hyung Kwon Byeon et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Mitogen-Activated Protein Kinase (MAPK): New Insights in Breast Cancer
Huanyu Lu et al.
JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY (2019)
KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician
Vlad-Adrian Afrasanie et al.
RADIOLOGY AND ONCOLOGY (2019)
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Eskil Eskilsson et al.
NEURO-ONCOLOGY (2018)
HER2-positive breast cancer: Current and new therapeutic strategies
Santiago Escriva-de-Romani et al.
BREAST (2018)
Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer
Renata Duchnowska et al.
CANCER TREATMENT REVIEWS (2018)
Circulating tumour DNA in EGFR-mutant non-small-cell lung cancer
M. Cabanero et al.
CURRENT ONCOLOGY (2018)
HER2: An emerging target in colorectal cancer
Megan Greally et al.
CURRENT PROBLEMS IN CANCER (2018)
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
Zhenyi An et al.
ONCOGENE (2018)
EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance
Stefano Fogli et al.
PHARMACOGENOMICS (2018)
Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
Joan Rou-En Choo et al.
TARGETED ONCOLOGY (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
Metastatic and triple-negative breast cancer: challenges and treatment options
Sumayah Al-Mahmood et al.
DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2018)
The role of pazopanib on tumour angiogenesis and in the management of cancers: A review
Dinesh Kumar Chellappan et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)